Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) have been given a consensus rating of “Moderate Buy” by the eight research firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, four have assigned a buy rating and two have assigned a strong buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $43.40.

Several equities research analysts recently commented on the company. UBS Group assumed coverage on Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, February 17th. They issued a “buy” rating and a $45.00 price target for the company. Zacks Research raised Damora Therapeutics, Inc. Common Stock to a “hold” rating in a research note on Friday, January 9th. Guggenheim reissued a “buy” rating and issued a $40.00 price target (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, February 17th. Lifesci Capital raised Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research report on Monday, February 2nd. Finally, Royal Bank Of Canada began coverage on Damora Therapeutics, Inc. Common Stock in a research note on Friday, April 24th. They set an “outperform” rating and a $40.00 price target for the company.

Damora Therapeutics, Inc. Common Stock Stock Performance

Shares of NASDAQ DMRA opened at $23.93 on Thursday. The stock has a market cap of $1.44 billion, a price-to-earnings ratio of -1.98 and a beta of 1.59. The business has a 50 day simple moving average of $26.73 and a 200 day simple moving average of $23.03. Damora Therapeutics, Inc. Common Stock has a 52 week low of $2.45 and a 52 week high of $38.33.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

A number of large investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC bought a new stake in Damora Therapeutics, Inc. Common Stock during the fourth quarter worth approximately $40,000. Geode Capital Management LLC bought a new stake in Damora Therapeutics, Inc. Common Stock during the fourth quarter worth approximately $266,000. Virtu Financial LLC bought a new stake in Damora Therapeutics, Inc. Common Stock during the third quarter worth approximately $49,000. Sigma Planning Corp bought a new stake in Damora Therapeutics, Inc. Common Stock during the fourth quarter worth approximately $334,000. Finally, Two Sigma Investments LP bought a new stake in Damora Therapeutics, Inc. Common Stock during the third quarter worth approximately $76,000. Institutional investors own 14.20% of the company’s stock.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.